Doctors at Evelina Children's Hospital in London have invented one of Europe's top-selling medical iPhone applications, with more than 100 downloads every week. The Paediatric Emergency Drugs app enables medical and nursing staff to quickly work out complicated drug calculations during emergencies to ensure paediatric patients receive the correct drug doses for their age and weight. Paediatric intensive care consultant, Dr Shelley Riphagen, came up with the idea with the help of Dr Andrew Durward's IT skills and the app went on sale in March this year. Dr Riphagen said: "When critically-ill children present to district general hospitals with emergencies, the right doses of drugs according to the child's age and weight need to be available immediately. The Paediatric Emergency Drugs app allows this to happen. It has made a huge difference to the care of our patients and it's really fantastic to know that it's also appreciated by medical and nursing staff in hospitals across Europe." The project was made possible through collaboration with UBQO.
Medical app is best seller
You may also like
Ingredients
dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations
Read moreThe new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Trending Articles
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists